July 1, 1998Journal of Clinical Oncology
Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen.
Why the study?
Does intracavitary thiotepa improve symptoms and prevent progression in patients with malignant symptomatic pericardial effusion?
Population
23 patients with malignant symptomatic pericardial effusion
Design
Case_series
Follow-up
median time to progression 8.9 months (range 1 to 26)
Authors
Discussion
Loading...
Member takes
Implication
May support symptom management in malignant pericardial effusion; hypothesis-generating and requires randomized confirmation.
Structured PICO
Does intracavitary thiotepa improve symptoms and prevent progression in patients with malignant symptomatic pericardial effusion?
P
Population
23 patients with malignant symptomatic pericardial effusion (9 breast cancer, 11 lung cancer, 2 unknown primary tumor, 1 metastatic melanoma)
I
Intervention
Intracavitary thiotepa (15 mg on days 1, 3, and 5) through an indwelling pericardial cannula after extraction of as much pericardial fluid as possible on day 0
O
Outcome
Response to treatment assessed by clinical examination, CT scan, and echocardiography, and time to pericardial effusion progressionsurrogate
A short course of intracavitary thiotepa is highly effective and well-tolerated for managing malignant pericardial effusions.
Cite This Study
Colleoni et al. (1998) studied this question.